Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: Implications for altered anti-cancer effects and pharmacological properties

British Journal of Pharmacology

Volumn 158, Issue 4, 2009, Pages 1153-1164

  Hegedus, C ^a   Ozvegy Laczka C ^a   Apati A A ^a   Magocsi M ^a   Nemet K ^a   Orfi, L ^a   Keri G ^b   Katona, M ^b   Takats Z ^b   Varadi A ^b   Szakacs G ^a   Sarkadi, B ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

ABCB1; ABCG2; ADME Tox; Bcr Abl; CML; MDR; TKI

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BCR ABL PROTEIN; BOSUTINIB; BREAST CANCER RESISTANCE PROTEIN; DASATINIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; FUSION PROTEINS, BCR-ABL; HUMANS; INDOLES; K562 CELLS; NEOPLASM PROTEINS; NEOPLASMS; NITRILES; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINOLINES; SUBSTRATE SPECIFICITY; THIAZOLES;

EID: 70350132811     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00383.x     Document Type: Article

References (39)

1. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S et al. (2007). Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21 : 1267 1275.
2. Brozik A, Casey NP, Hegedus C, Bors A, Kozma A, Andrikovics H et al. (2006). Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK. Ann N Y Acad Sci 1090 : 344 354.
3. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al. (2004). Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104 : 2940 2942.
4. Dean M, Fojo T, Bates S (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5 : 275 284.
5. Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y et al. (2008). Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32 : 980 983.
6. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O et al. (2005). Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65 : 1770 1777.
7. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112 : 3348 3354.
8. Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 : 48 58.
9. Hamada A, Miyano H, Watanabe H, Saito H (2003). Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307 : 824 828.
10. Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C et al. (2008). Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14 : 5325 5331.
11. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G (2002). Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587 : 318 325.
12. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P et al. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14 : 3881 3888.
13. Hollo Z, Homolya L, Davis CW, Sarkadi B (1994). Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191 : 384 388.
14. Hollo Z, Homolya L, Hegedus T, Sarkadi B (1996). Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383 : 99 104.
15. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E et al. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64 : 2333 2337.
16. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. (2007). Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21 : 926 935.
17. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC (2006). Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108 : 1370 1373.
18. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL (2007). Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109 : 4016 4019.
19. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M et al. (2002). The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8 : 22 28.
20. Kotaki M, Motoji T, Takanashi M, Wang YH, Mizoguchi H (2003). Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. Cancer Lett 199 : 61 68.
21. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. (2003). MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 : 2368 2373.
22. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F et al. (2008). Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68 : 9809 9816.
23. Nakanishi T, Shiozawa K, Hassel BA, Ross DD (2006). Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108 : 678 684.
24. Ozvegy C, Varadi A, Sarkadi B (2002). Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 277 : 47980 47990.
25. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A et al. (2004). High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65 : 1485 1495.
26. Ozvegy-Laczka C, Laczko R, Hegedus C, Litman T, Varady G, Goda K et al. (2008). Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J Biol Chem 283 : 26059 26070.
27. Quintas-Cardama A, Kantarjian H, Cortes J (2007). Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6 : 834 848.
28. Ren R (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5 : 172 183.
29. Sarkadi B, Homolya L, Szakacs G, Varadi A (2006). Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86 : 1179 1236.
30. Scharenberg CW, Harkey MA, Torok-Storb B (2002). The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99 : 507 512.
31. Smeets M, Raymakers R, Vierwinden G, Pennings A, van de Locht L, Wessels H et al. (1997). A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol 96 : 346 355.
32. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13 : 379 393.
33. Telbisz A, Muller M, Ozvegy-Laczka C, Homolya L, Szente L, Varadi A et al. (2007). Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim Biophys Acta 1768 : 2698 2713.
34. Thomas J, Wang L, Clark RE, Pirmohamed M (2004). Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 : 3739 3745.
35. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A et al. (2007a). Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 109 : 2112 2120.
36. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007b). Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7 : 345 356.
37. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. (2006). OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 : 697 704.
38. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP (2007). Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 109 : 3609 3610.
39. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7 : 1028 1034.